

[REDACTED]

**From:** SKERRITT, John  
**Sent:** Wednesday, 20 January 2016 9:15 AM  
**To:** [REDACTED]; KELLY, Larry; HORNER PSM, Philippa; [REDACTED];  
**Cc:** [REDACTED]; MCRAE, Cheryl; [REDACTED]  
**Subject:** URGENT Draft calculations - change in regulatory burden from implementation of MMDR recommendations [DLM=Sensitive]  
**Attachments:** Calculation of regulatory burden measurement by E and Y for MMDR 19 1 16.xlsx  
**Importance:** High

Colleagues

Thanks to those of you who were able to attend the workshop on Friday 8 January with E&Y on calculating increases and decreases in regulatory burden associated with potential implementation of different recommendations of the MMDR. To recap, this is a critical part of the information that Ministers need in considering the potential merits and impact of individual recommendations and together with colleagues from Woden I will be meeting with both Ministers and their staff on this coming Friday as well as next Wednesday.

So while its recognised that the numbers put forward involve a long list of assumptions, it's important for them to be as realistic as possible. Please find below an email from EY attaching the draft model on the estimated change in regulatory burden for medicines and medical devices. I'm told by the MMDR team at Woden EY received the outstanding information from TGA yesterday afternoon and is yet to receive the data from PBS to further inform certain calculations.

As the source of expertise that would enable the figures to be as realistic as possible, it's important that we at TGA review these numbers. We need to review them ASAP – and provide feedback by 10 am tomorrow given that the meeting with the MO is Friday. Can I ask the key Branch and Division heads to collate feedback to me on this. I'm aware that the following folks are away at present: [REDACTED], Cheryl McRae

The data is not in the most user-friendly form – some spreadsheets are massive and have embedded figures. While I will ask E&Y to fix this up in the final report we don't have time to ask them to fix it now and send the excel file back to us.

I will spend a couple of hours on the data this morning checking the calculations and assumptions behind the headline figures, but some initial feelings from me / and specific questions for the relevant branches are:

- The Prescription medicines numbers (regulatory saves) now seem too high – they are based on cancer meds profitability and I don't think these are representative of the profitability of the mainstream innovator medicines for chronic diseases. The business model for the latter is different – moderate profits per annum, but recognising that unlike cancer medicines these are taken for many years. Can the people in the Prescription medicines branch please also check the figures around variations which also seem too high ?
- The generics numbers (regulatory saves) seem too low – perhaps the changes in business processes have not been captured ?
- I'm not surprised that there is a small increase in regulatory burden for the unapproved therapeutics area – do we need to think more about how we are proposing for the electronic system to be introduced/ implemented ?



Should there be an initial increase in burden followed by a decrease over years 3-10 ? After all if it's going to increase burden for the users why would the MMDR be so hot on it and why would we push to implement it ?

- Not surprised that the comp meds work sees an increase in burden and that some of the recs that we have agreed to propose to government NOT be implemented would reduce the increase in burden, but keen to have these figures checked, please.
- Advertising burden changes seem small ?
- Not surprised at the significant increase in burden that a delay associated with possible CMO approvals would bring. I assume that this has been calculated across all products, which is fine for now as it provides metrics for the Minister. The take home message is that a delay of 3 months associated with CMO approvals would wipe out all of the calculated regulatory burden reductions arising from the MMDR. Simple message.

Anyhow, please do make it a priority today to spend some time looking at the assumptions that relate to your area in particular, and get back to me please through your branch/ division head .

thanks

John

**Adjunct Prof John Skerritt FTSE FIPAA (Vic)**

**Deputy Secretary for Regulatory Services  
Department of Health**

PO Box 100 Woden ACT 2606 Australia

Phone: [REDACTED] Fax: (02) 6203 1265

Email: [REDACTED]

---

**From:** [REDACTED]  
**Sent:** Tuesday, 19 January 2016 5:23 PM  
**To:** [REDACTED]  
**Cc:** MMD Review Taskforce; [REDACTED]  
**Subject:** Draft model - change in regulatory burden [SEC=No Protective Marking]

This email is to be read subject to the disclaimer below.

Hi [REDACTED]

Please find attached the draft model calculating the estimated change in the regulatory burden for medicines and medical devices, updated as per our discussion this afternoon. As discussed with you, the model is currently undergoing further internal QA review and so should be considered an initial draft only.

I am still waiting for the data from the PBS area on new NCE and generic listings on the PBS to further inform the calculation of the profit per day metric for NCEs (and the extension of indication variations) and generics. The previous discussion I have had with the PBS area is that they will provide 12 months of data (3 years was viewed as unmanageable in the timeframes) on all new NCE listings and generic listings including the ex-manufacturer sales revenue and number of listings. This will be used to inform the profit per day metric.

The current approach for NCEs is based on the estimated profitability of the top 100 cancer medicines. As you will see, the reduction in delay costs for NCEs and variations is responsible for around 85% of the reduction in the regulatory burden. As a result, the profit per day metric is highly integral to the overall result (as small changes will dramatically impact the overall result) and so it will be critical to agree the relevant assumptions with TGA and yourselves.

Using the assumption for NCE profitability described above, the initial estimate of the average annual reduction in the regulatory burden is \$134.6m. The estimated change in the regulatory burden for each category is detailed in the table below.

The figures in the table below include the costs associated with the high risk devices register (Rec 22(1)) and the recommendations that will increase the burden on complementary medicine sponsors (publishing evidence on website (Rec 43), including prominent disclaimer on all promotional products(Rec 44)) that I understand do not have the support of the department.

Summary of deregulatory savings	Average annual change in regulatory burden
	Negative = increase in regulatory burden Positive = reduction in regulatory burden
NCEs	\$41,951,684
Generics	\$34,477
Variations	\$70,362,425
Unapproved therapeutics	-\$298,305
Complementary medicines	-\$3,528,170
Medical devices	\$25,538,108
Advertising and complaints resolution	\$574,365
<b>TOTAL</b>	<b>\$134,634,585</b>

These figures relating to Recs 22(1), 43 and 44 can be easily removed from the model - the estimated average annual reduction in the regulatory burden then increases to \$137.1m (it increases because those recommendations are assumed to increase the regulatory burden).

Summary of deregulatory savings <b>EXCLUDING: regulatory costs arising from high risk device register, and publishing efficacy (comp meds) and changing labels (comp meds)</b>	Average annual change in regulatory burden
	Negative = increase in regulatory burden Positive = reduction in regulatory burden
NCEs	\$41,951,684
Generics	\$34,477
Variations	\$70,362,425
Unapproved therapeutics	-\$298,305
Complementary medicines	-\$2,232,673
Medical devices	\$26,754,962
Advertising and complaints resolution	\$574,365
<b>TOTAL</b>	<b>\$137,146,935</b>

The tables above do not include quantification of the increase in regulatory burden that is assumed to arise if Rec 29(1)(a) is implemented (the Chief Medical Officer becomes the delegate for decisions). In the workshop held on 8 January, John requested an two different scenarios be quantified: one where the implementation of Rec 29(a)(a) increases the average length of time it takes the TGA to assess an application (for NCEs, major variations, generics and high risk devices) by 3 months and a second where it increases the assessment timeframes by six months.

The average annual increase in the regulatory burden is detailed in the table below (\$122m for 3 month increase and \$244m for 6 month increase).

Indicative <b>increase</b> in average annual regulatory delay costs (for NCEs (including variations for new fixed dose and extension of indications), generics and high risk medical devices) from implementation of Recommendation 29(1)(a) - the CMO becomes the delegate for decisions	
Option 1 - 91 day (3 month) increase in TGA assessment timeframes	-\$122,055,981
Option 2 - 182 day (6 month) increase in TGA assessment timeframes	-\$244,111,961

As discussed with you, it would be good to seek a further round of feedback from relevant subject matter experts to confirm the assumptions are reasonable in light of the estimated outcomes.

Regards



[Redacted] | Economics, Regulation and Policy Group

Ernst & Young

